AAD 2023: Bimekizumab Shows Promising Results in Treatment of Moderate-to-Severe Hidradenitis Suppurativa
Significantly greater number of patients receiving bimekizumab versus placebo achieved response, maintained to week 48
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.